Valuation
- Market cap
- 6,000
- Revenue TTM
- $5,330,000
- Net income TTM
- $-72,530,000
- P/E (trailing)
- 0.00
- P/E (forward)
- —
- Profit margin
- -1,360.79%
- Debt to equity
- 0.00
Trading
- Volume
- 2,900
- Avg volume
- —
- Day's range
- $0.00 – $0.00
- Shares out
- 61,748,000
- Stochastic %K
- —
- Beta
- -5.07
- Analysts
- —
- Price target
- $5.50
Company profile
Athersys, Inc., a clinical-stage biotechnology company, develops therapies in the regenerative medicine area. Its stem cell product candidate is the MultiStem cell therapy, an allogeneic stem cell product for the treatment of indications in the neurological, inflammatory and immune, and cardiovascular disease areas, as well as other critical care conditions. The company was founded in 1995 and is headquartered in Cle...
Show more
Athersys, Inc., a clinical-stage biotechnology company, develops therapies in the regenerative medicine area. Its stem cell product candidate is the MultiStem cell therapy, an allogeneic stem cell product for the treatment of indications in the neurological, inflammatory and immune, and cardiovascular disease areas, as well as other critical care conditions. The company was founded in 1995 and is headquartered in Cleveland, Ohio. On September 24, 2024, the voluntary petition of Athersys, Inc. for reorganization under Chapter 11 was converted to Chapter 7. It had filed for Chapter 11 bankruptcy along with its affiliates on January 5, 2024.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 216 431 9900
- Website
- https://www.athersys.com
- Address
- 3201 Carnegie Avenue, Cleveland, United States
Latest news
No headlines yet.
